Steve Perrin, PhD (CEO/CSO of ALS TDI) will give the latest update on the clinical development plans for AT-1501 and will review exciting early outcomes from the Precision Medicine Program (PMP). He will discuss the long and short term goals of the program and what that means for those living with ALS today and how it will affect future drug development in ALS.
Register today to find out more about these programs and hear about other drugs in development at ALS TDI.